Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma
Igor Puzanov, Mohammed Milhem, Robert Andtbacka, David Minor, Omid Hamid, Ai Li, Ari VanderWalde, Howard Kaufman
Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P84; DOI: 10.1186/2051-1426-1-S1-P84